Biofrontera reports first-half 2026 results, sales rise 44.3%
The biopharmaceutical company said European sales revenue rose to EUR 9.0 million in the first half of 2026 and EBITDA from continuing operations improved to EUR 1.7 million. It also reported record Ameluz unit sales in Germany and higher cash of EUR 7.1 million.
Story updates
2026/13:30 UTC+2) Leverkusen, September 30, 2026 — Biofrontera AG (ISIN: DE000A4BGGM7), an international biopharmaceutical company specialized in dermatology, today announced its financial results for the first six months ended June 30, 2026. 0 million partly driven by temporary wholesaler stocking in Germany ahead of the July Ameluz® price increase. 3 million in H1 2025. S.
1 million). 5 million. 3%. Ovixan® continued its successful market expansion in the United Kingdom following its launch in Q1 2026.
6 million at year-end 2025. 96)% "The first half of 2026 clearly demonstrates the improvement in the underlying performance of our European business. We achieved strong revenue growth and, more importantly, returned continuing operations to positive EBITDA. The German business benefited from a temporary stocking effect ahead of the July price increase, but underlying in-market demand also remained strong, with record Ameluz® unit sales.
At the same time, the launch of Ovixan® in the UK and the continued growth of our partner markets confirm the potential of our strategy to leverage our dermatology infrastructure across a broader portfolio. 3%. 8 million. This increase was partly attributable to higher inventory levels at German wholesalers ahead of the Ameluz® price increase implemented in July 2026.
Management expects this temporary stocking effect to reverse over the coming months as inventory levels normalize. Underlying market demand remained positive. 3% compared with H1 2025. 3%.
In the United Kingdom, Biofrontera successfully launched Ovixan® in Q1 2026. The product developed in line with management expectations during the first quarter, with the positive launch performance consolidating further in Q2. Ovixan® complements Ameluz®, Skinoren® and Advantan® and supports Biofrontera's strategy of broadening its dermatology portfolio by leveraging its existing commercial infrastructure. 0%.
4 million, primarily due to the optimization of the Group's organizational structure and the absence of new litigation requiring additional legal provisions. 1 million, partly due to preliminary work on potential new indications for Ameluz®. 3 million in H1 2025. 3 million.
The improvement reflects the strong revenue development, the optimized cost structure and the increased operational focus on the European business. S. S. -related activities are reported as discontinued operations.
The earn-out received from Biofrontera Inc. 6 million in H1 2025, and is recorded in other income rather than sales revenue. 1 million in the prior-year period. The positive development in the market value of Biofrontera Inc.
8 million in H1 2026. 7 million in H1 2025. 6 million as of December 31, 2025. 4 million in the prior-year period.
Based on current corporate planning, the Group expects to maintain sufficient liquidity to meet all obligations for at least the next twelve months. Outlook Biofrontera confirms the financial guidance for fiscal year 2026 published in March 2026. The Company expects full-year revenue growth to normalize as the temporary German stocking effect unwinds. Management continues to focus on Group sales and adjusted and unadjusted EBITDA as key performance indicators.
S. 0 million Looking beyond 2026, Biofrontera intends to pursue growth along three complementary paths: expanding Ameluz® into additional territories, adding selected dermatology products through licensing or acquisitions, and evaluating potential additional indications for Ameluz®. The complete Half-Year Financial Report 2026 is available on the Biofrontera AG website under Investors & Media / Financial Reports. About Biofrontera Biofrontera AG is a biopharmaceutical company founded in 1997 that specializes in the development and distribution of dermatological drugs.
Based in Germany, the Company develops and markets innovative products for the treatment of the skin. The Company's leading product is Ameluz®, a prescription topical drug used in photodynamic therapy for certain superficial skin cancers and their precursors. Ameluz® has been marketed in the EU since 2012. Biofrontera is one of the first German biopharmaceutical companies to have received a centralized European approval as well as an approval in the United Kingdom for a drug it developed in-house.
com Website: ISIN(s): DE000A4BGGM7 (Share) Stock Exchange(s): Regulated Market in Dusseldorf, Frankfurt; Free Market in Munich, Stuttgart, Tradegate BSX [ source: ] (c) pressetext Nachrichtenagentur GmbH Ad-hoc and financial news distributed by pressetext. Archive: The emitter is responsible for the content. com or +43-1-81140-0.